RESUMO
DNA-based immunizations have been used to elicit cellular immunity to hepatitis C virus (HCV) proteins in mice. Mice were immunized by intramuscular or intradermal injections of plasmid DNA derived from a near-full-length HCV genotype 1b genomic clone (pRC/B2) or individual genomic clones. These immunizations induced cytotoxic T lymphocytes (CTLs), as revealed in standard chromium-release assays that used syngeneic peptide-pulsed or transfected target cells. These assays identified four CTL epitopes within the capsid, E1, and E2 regions of the polyprotein sequence of HCV genotype 1a that were cross-reactive with HCV genotype 1b. Additionally, CTLs derived from mice immunized with either NS3 or NS5 specifically lysed target cells sensitized to either the genotype 1a or 1b gene products. Nucleic acid immunizations also generated humoral immunity to HCV proteins, as detected by anti-HCV reactivity to NS3 and capsid in ELISAs and immunoblot assays.
Assuntos
Hepacivirus/imunologia , Vacinas de DNA/imunologia , Vacinas contra Hepatite Viral/imunologia , Proteínas não Estruturais Virais/imunologia , Proteínas Estruturais Virais/imunologia , Animais , Especificidade de Anticorpos , Sequência de Bases , DNA Complementar/imunologia , Ensaio de Imunoadsorção Enzimática , Feminino , Genótipo , Hepacivirus/classificação , Hepacivirus/genética , Hepatite C/imunologia , Hepatite C/prevenção & controle , Anticorpos Anti-Hepatite C/sangue , Imunidade Celular , Camundongos , Camundongos Endogâmicos BALB C , Dados de Sequência Molecular , Plasmídeos , VacinaçãoAssuntos
Vacinas contra a AIDS , Síndrome da Imunodeficiência Adquirida , Modelos Animais de Doenças , HIV/patogenicidade , Pan troglodytes/virologia , Síndrome da Imunodeficiência Adquirida/prevenção & controle , Síndrome da Imunodeficiência Adquirida/virologia , Animais , Bioética , Avaliação Pré-Clínica de Medicamentos , VirulênciaAssuntos
Vacinas contra a AIDS , Infecções por HIV/prevenção & controle , HIV-1/patogenicidade , Pan troglodytes , Animais , Avaliação Pré-Clínica de Medicamentos , Infecções por HIV/virologia , HIV-1/fisiologia , Pan troglodytes/virologia , Viremia/prevenção & controle , Virulência , Replicação ViralAssuntos
Antivirais/efeitos adversos , Arabinofuranosiluracila/análogos & derivados , Modelos Animais de Doenças , Hepatite/tratamento farmacológico , Animais , Arabinofuranosiluracila/efeitos adversos , Doença Crônica , Avaliação Pré-Clínica de Medicamentos/métodos , Humanos , Marmota , Pan troglodytesRESUMO
The identification and characterization of a recombinant cDNA clone, designated OV9M, expressing an antigen present in Onchocerca volvulus infective larvae and adult stages is described. Clone OV9M was identified by screening a lambda gt11 cDNA expression library derived from adult O. volvulus mRNA using pooled rabbit antisera raised against the third (L3) and fourth (L4) stage larvae of the parasite. The cDNA clone encodes an open reading frame of 238 amino acids corresponding to a 27-kDa polypeptide. This polypeptide contains a series of five highly conserved repeats of 25 amino acids that are similar to repeats found in calponin, a protein previously only identified in vertebrate smooth muscle. Extension of the 5' end of the cDNA clone revealed two additional repeats extending the sequence to 378 amino acids, encoding a 41.8-kDa protein. Affinity purified antibodies, which bound specifically to the glutathione S-transferase-OV9M fusion polypeptide, recognize a series of antigens in extracts of O.volvulus microfilariae, L3, L4 and adult stages. The apparent molecular weight of the native OV9M protein in the adult is 45 kDa. Similar proteins are present in extracts of other nematodes including Caenorhabditis elegans, and antibodies from other filarial infections are cross reactive with glutathione S-transferase-OV9M fusion polypeptide. Immunoelectron microscopy revealed that the antigen encoded by this clone is present in the longitudinal muscles of the various larval stages and adult worms. Antibodies to the OV9M protein are present in 40-60% of both patently infected and non-patent individuals residing in onchocerciasis endemic areas.
Assuntos
Proteínas de Ligação ao Cálcio/genética , DNA de Helmintos/genética , Proteínas de Helminto/genética , Onchocerca volvulus/genética , Sequência de Aminoácidos , Animais , Antígenos de Helmintos/metabolismo , Sequência de Bases , Proteínas de Ligação ao Cálcio/imunologia , Proteínas de Ligação ao Cálcio/metabolismo , Clonagem Molecular , DNA Complementar/genética , Genes de Helmintos , Proteínas de Helminto/imunologia , Proteínas de Helminto/metabolismo , Humanos , Proteínas dos Microfilamentos , Microscopia Imunoeletrônica , Dados de Sequência Molecular , Peso Molecular , Onchocerca volvulus/imunologia , Onchocerca volvulus/metabolismo , Oncocercose/imunologia , Homologia de Sequência de Aminoácidos , CalponinasRESUMO
The treatment of plasma with organic solvent/detergent mixtures at the time of plasma collection or pooling could reduce the exposure of technical staff to infectious viruses and enhance the viral safety of the final product. Treatment of plasma for 4 hours with 2-percent tri(n-butyl)phosphate (TNBP) at 37 degrees C, with 1-percent TNBP and 1-percent polyoxyethylensorbitan monooleate (Tween 80) at 30 degrees C, or with 1-percent TNBP and 1-percent polyoxyethylene ethers, (Triton X-45) at 30 degrees C resulted in the rapid and complete inactivation of greater than or equal to 10(4) tissue culture-infectious doses (TCID50) of vesicular stomatitis and Sindbis viruses, which are used as surrogates. Treatment of plasma with TNBP and TNBP and Tween-80 was shown to inactivate greater than or equal to 10(4) TCID50 of human immunodeficiency virus. TNBP treatment of plasma contaminated with 10(6) chimpanzee-infectious doses (CID50) of hepatitis B virus and 10(5) CID50 of non-A,non-B hepatitis virus prevented the transmission of hepatitis to chimpanzees. Immediately after treatment of plasma with 2-percent TNBP, the recovery of factors VIII, IX, and V and antithrombin III was 80, 90, 40, and 100 percent, respectively. Recovery of all factors was greater than or equal to 90 percent after treatment with TNBP and detergent mixtures. Treated plasma was fractionated by standard techniques into antihemophilic factor and prothrombin complex concentrates, immune globulin, and albumin. Prior treatment with TNBP or TNBP and detergent did not affect the separations of desired proteins. Therefore, it appears possible to inactivate viruses in plasma before the execution of standard fractionation procedures.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Detergentes , HIV/efeitos dos fármacos , Vírus de Hepatite/efeitos dos fármacos , Organofosfatos , Compostos Organofosforados , Plasma/microbiologia , Tensoativos , Ativação Viral/efeitos dos fármacos , Proteínas Sanguíneas/fisiologia , Fracionamento Celular , Detergentes/farmacologia , HIV/fisiologia , Vírus de Hepatite/fisiologia , Humanos , Organofosfatos/farmacologia , Plasma/efeitos dos fármacos , Óleo de Soja/farmacologia , Ativação Viral/fisiologiaRESUMO
beta-propiolactone (beta-PL) treatment has been evaluated for its ability to inactivate 10(3.5) chimpanzee infectious doses (CID50) of the Hutchinson strain of hepatitis non-A, non-B virus (HNANBV). Two chimpanzees were inoculated with a beta-PL-treated immunoglobulin solution to which this dose of the titrated virus had been added prior to beta-PL treatment. beta-PL treatment was performed in accordance with the production procedure used for a licensed intravenous immunoglobulin preparation. Neither animal developed hepatitis. When subsequently challenged with the same spiked immunoglobulin solution that had not been beta-PL treated, both animals developed clear-cut hepatitis non-A, non-B. The results of this experiment demonstrate that beta-PL treatment is effective for the inactivation of hepatitis non-A, non-B virus in intravenous immunoglobulin.
Assuntos
Hepatite C/prevenção & controle , Vírus de Hepatite/efeitos dos fármacos , Hepatite Viral Humana/prevenção & controle , Imunoglobulinas/efeitos adversos , Lactonas/farmacologia , Propiolactona/farmacologia , Animais , Antivirais , Contaminação de Medicamentos , Avaliação Pré-Clínica de Medicamentos , Feminino , Hepatite C/transmissão , Imunoglobulinas/administração & dosagem , Injeções Intravenosas , Pan troglodytesRESUMO
The bivalent form of an aqueous formalin-inactivated hepatitis B vaccine was evaluated for safety and immunogenicity in chimpanzees. To evaluate safety five animals were inoculated intravenously with vaccine containing 500 micrograms HBsAg and two animals with 50 micrograms. None of these animals developed hepatitis or any serologic marker indicative of the presence of residual live virus in the vaccine. Twenty-four animals were used to evaluate immunogenicity and protective efficacy. Seven of these immunized animals produced weak or no anti-HBs responses. Two doses of 50 micrograms HBsAg given subcutaneously 1 month apart protected each of four animals that were challenged with 10(3.5) CID50 HBV at 6 and 12 months after immunization and protected three of four animals challenged at 24 months against development of hepatitis or HBsAg. Three of 4 animals in each group immunized with two doses of 20, 10, or 5 micrograms HBsAg were similarly protected when challenged 6 months after immunization. Thirteen of 20 immunized animals that did not develop HBsAg after challenge with HBV developed anamnestic anti-HBs or anti-HBc responses between 2 and 18 months after challenge, indicating minimal replication of challenge virus. The time of onset and frequency of occurrence of these delayed responses was related to the titer of anti-HBs at the time of challenge. False positive Ausab test results were observed in quarantined chimpanzees. These were neither preceded by appearance of HBsAg nor accompanied by development of anti-HBc. In most cases these reactions were due to a reactant having a sedimentation coefficient and an electrophoretic mobility resembling that of IgM. This reactant generally did not appear to confer resistance to challenge with HBV. The humoral immune response was characterized as being entirely of the IgM class 2 weeks after immunization and switched entirely into the IgG class by 10-12 weeks after vaccine administration. At the time of challenge all animals with antibody had anti-HBs of subtype a.
Assuntos
Hepatite B/prevenção & controle , Vacinas contra Hepatite Viral/farmacologia , Animais , Avaliação Pré-Clínica de Medicamentos , Hepatite B/imunologia , Antígenos de Superfície da Hepatite B/análise , Vacinas contra Hepatite B , Pan troglodytes , Vacinas contra Hepatite Viral/toxicidadeRESUMO
The structural aspects of SH antigen-containing particles were investigated. These studies confirmed the existence of a large spherical particle (ca. 43 nm) and smaller (ca. 20 nm) rod- and sphere-shaped particles. The large particle consists of an outer and inner membrane and a core of "nucleic acid" as seen by positive staining techniques. The outer membrane of the large particle appears to be similar to that of the 20-nm diameter spheres and rods known to possess the SH antigen.